Boston, MA 06/05/2013 (wallstreetpr) – The share prices of Pluristem Therapeutics Inc. (NASDAQ:PSTI) had declined by 14.37 percent to close at $2.86 per share for the last trading session on Tuesday. The shares of the bio therapeutics company had been trading in the range of $2.47 to $2.95 per share almost closer to its year low price. The shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) had recorded 52 week low price level of $2.26 per share and 52 week high price level of $5 per share.
The bio therapeutics company, Pluristem Therapeutics Inc. (NASDAQ:PSTI) had been engaged in the development and commercialization of non personalized cell therapy products. The products of the company are aimed at treating a wide range of severe degenerative, ischemic and auto immune disorders.
Pluristem Therapeutics Inc. (NASDAQ:PSTI) is presently being subject to investigations by Bronstein, Gewaritz and Grossman LLC on behalf of claims by the investors. The investigating firm is probing into whether the company had violated federal securities laws. The recent decline in share prices of Pluristem Therapeutics Inc. (NASDAQ:PSTI) are owed to the clinical hold of its mid stage trial of the company’s experimental muscle pain drug. The clinical hold of this drug was imposed by the Food and Drug Administration of the United States.
The shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) had witnessed heavy trading volume at 1.83 million shares being exchanged in Tuesday, while the average volume is just 149,434 shares per day. The company presently holds 58.33 million shares outstanding in the market.
